Table 2. Immune Activation Panel corresponding to HIV+ subjects enrolled per study groupa , b.
| Median % (IQ) | ||||||
| Group (No. of subjects) | CD4/CD38 | CD4/HLA-DR | CD4/CD38/HLA-DR | CD8/CD38 | CD8/HLA-DR | CD8/CD38/HLA-DR |
| PHI | ||||||
| All (n = 32) | 21.7 (13.8–35.1) | 5.0 (1.5.–8.4) | 1.4 (0.4–2.2) | 44.3 (22.5–55.7) | 32.4 (15.5–44.8) | 15.8 (7.4–34.7) |
| PHI >350 (n = 20) | 23.1 (13.8–33.4) | 6.7 (1.5–6.4) | 1.2 (0.4–2.1) | 33.7 (21.3–48.5) | 24.9 (11.8–39.7) | 9.7 (6.0–27.8) |
| PHI <350 (n = 12) | 18.3 (11.9–36.3) | 8.2 (1.4–12.6) | 1.5 (0.5–5.6) | 48.2 (39.0–64.1) | 40.2 (27.9–57.8) | 33.4 (14.8–43.6) |
| Chronic (n = 10) | 41.3 (28.1–46.1) | 12.0 (5.2–18.5) | 2.7 (1.1–18.5) | 35.9 (24.4–91.7) | 19.0 (18.2–49.8) | 11.2 (5.6–24.4) |
| EC (n = 11) | 22.6 (12.9–32.9) | 4.7 (2.3–9.1) | 0.6 (0.4–1.7) | 33.5 (28.2–44.5) | 17.2 (12.3–31.9) | 8.2 (3.2–12.8) |
a
Flow cytometry double platform, FACSCanto, BD Biosciences.
b
For PHI subjects, data correspond to baseline samples. For chronic and elite controller subjects, data correspond to samples obtained at enrollment.
IQ: Interquartile range.